GlassScriptPhysician profile
Farrah Farquharson
NPI 1144502154
$8,220.53
in general payments reported to CMS, 2019-2025
55 companies · $94.28 in 2025
The $94.28 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,236 · 2022: $2,161 · 2023: $2,227 · 2024: $1,502 · 2025: $94.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,025 · Long Term Medical Supply Or Device Loan: $698 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,024.79 |
| Long Term Medical Supply Or Device Loan | $697.90 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $862.01 | 2021-2024 | |
| Celgene Corporation | $805.64 | 2021-2024 | Reblozyl, Opdualag |
| Astrazeneca Pharmaceuticals LP | $593.66 | 2021-2024 | Lynparza, Enhertu, Tagrisso |
| Seagen INC. | $540.40 | 2021-2023 | Padcev, Tukysa, Adcetris |
| Abbvie INC. | $485.13 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $459.10 | 2021-2024 | Opdivo |
| Incyte Corporation | $396.86 | 2021-2023 | Jakafi |
| Eisai INC. | $380.55 | 2021-2023 | |
| Genentech USA, INC. | $374.09 | 2022-2024 | Venclexta, Alecensa, Tecentriq |
| Pharmacyclics LLC, An Abbvie Company | $305.82 | 2021-2023 | Imbruvica |
| Janssen Biotech, INC. | $232.34 | 2021-2023 | Imbruvica, Darzalex |
| Genzyme Corporation | $224.12 | 2021-2023 | |
| Glaxosmithkline, LLC. | $200.46 | 2021-2023 | Shingrix, Jemperli, Zejula |
| Daiichi Sankyo INC. | $191.06 | 2021-2024 | Enhertu |
| Pfizer INC. | $178.84 | 2021-2024 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farrah Farquharson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.